|
Company announcement
|
Orphazyme A/S
| | No. 13/2017 | Ole Maaløes Vej 3 | | | DK-2200 Copenhagen N | | | | | |
www.orphazyme.com
| | | Company Registration No. 32266355 | | | | | | | | | 21 November 2017 |
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 ("Orphazyme"), hereby notifies receipt of information regarding the following grants under Orphazyme's long-term incentive programme as further described in company announcement 8/2017:
|
1
|
Details of the Reporting Person /
Closely Associated Person
| | a) | Name | Anders Hinsby | |
2
|
Reason for the notification
| | a) | Position/status | Chief Executive Officer | | b) | Initial notification/Amendment | Initial notification | |
3
|
Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
| | a) | Name | Orphazyme A/S | | b) | LEI code | 54930025OZD2GGSQ7L42 | |
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| | a) | Description of the financial instrument, type of instrument and identification code |
Rights to acquire or subscribe for matching shares and performance shares in Orphazyme A/S
ISIN DK0060910917
| | b) | Nature of the transaction |
Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive programme
| | c) | Price(s) and volume(s) | Price (s) | Volume(s) | | 0 | 5,000 (Matching shares) | | 0 | 30,000 (Performance shares assuming full vesting) | | d) |
Aggregated information
| | | e) | Date of the transaction | 2017-11-21 17:00 UTC+1 | | f) | Place of the transaction | Outside a trading venue |
|
1
|
Details of the Reporting Person /
Closely Associated Person
| | a) | Name | Anders Vadsholt | |
2
|
Reason for the notification
| | a) | Position/status | Chief Financial Officer | | b) | Initial notification/Amendment | Initial notification | |
3
|
Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
| | a) | Name | Orphazyme A/S | | b) | LEI code | 54930025OZD2GGSQ7L42 | |
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| | a) | Description of the financial instrument, type of instrument and identification code |
Rights to acquire or subscribe for matching shares and performance shares in Orphazyme A/S
ISIN DK0060910917
| | b) | Nature of the transaction |
Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive programme
| | c) | Price(s) and volume(s) | Price (s) | Volume(s) | | 0 | 4,000 (Matching shares) | | 0 | 16,000 (Performance shares assuming full vesting) | | d) |
Aggregated information
| | | e) | Date of the transaction | 2017-11-21 17:00 UTC+1 | | f) | Place of the transaction | Outside a trading venue |
|
1
|
Details of the Reporting Person /
Closely Associated Person
| | a) | Name | Thomas Kirkegaard Jensen | |
2
|
Reason for the notification
| | a) | Position/status | Chief Scientific Officer | | b) | Initial notification/Amendment | Initial notification | |
3
|
Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
| | a) | Name | Orphazyme A/S | | b) | LEI code | 54930025OZD2GGSQ7L42 | |
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| | a) | Description of the financial instrument, type of instrument and identification code |
Rights to acquire or subscribe for matching shares and performance shares in Orphazyme A/S
ISIN DK0060910917
| | b) | Nature of the transaction |
Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive programme
| | c) | Price(s) and volume(s) | Price (s) | Volume(s) | | 0 | 4,000 (Matching shares) | | 0 | 16,000 (Performance shares assuming full vesting) | | d) |
Aggregated information
| | | e) | Date of the transaction | 2017-11-21 17:00 UTC+1 | | f) | Place of the transaction | Outside a trading venue |
|
1
|
Details of the Reporting Person /
Closely Associated Person
| | a) | Name | Thomas Blaettler | |
2
|
Reason for the notification
| | a) | Position/status | Chief Medical Officer | | b) | Initial notification/Amendment | Initial notification | |
3
|
Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
| | a) | Name | Orphazyme A/S | | b) | LEI code | 54930025OZD2GGSQ7L42 | |
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| | a) | Description of the financial instrument, type of instrument and identification code |
Rights to acquire or subscribe for matching shares and performance shares in Orphazyme A/S
ISIN DK0060910917
| | b) | Nature of the transaction |
Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive programme
| | c) | Price(s) and volume(s) | Price (s) | Volume(s) | | 0 | 1,875 (Matching shares) | | 0 | 7,500 (Performance shares assuming full vesting) | | d) |
Aggregated information
| | | e) | Date of the transaction | 2017-11-21 17:00 UTC+1 | | f) | Place of the transaction | Outside a trading venue |
For additional information, please contact
Orphazyme
Anders Vadsholt, CFO +45 28 98 90 55
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orphazyme A/S via GlobeNewswire
HUG#2151187
|
